Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97990 | 0.76 | CA2 (0.57) | PPARGALDH1A1CA2CYP19A1NQO2 | |
| SCHEMBL96163 | 0.68 | CA2 (0.46) | PPARGALDH1A1GAACA2KDM4E | |
| SCHEMBL97252 | 0.66 | CA2 (0.45) | PPARGALDH1A1GAACA2KDM4E | |
| SCHEMBL97090 | 0.66 | CYP19A1 (0.42) | ALDH1A1HTTLMNAKMT2AGAA | |
| SCHEMBL98644 | 0.65 | KMT2A (0.46) | ALDH1A1KMT2ACYP19A1NQO2 | |
| SCHEMBL14438070 | 0.64 | CYP19A1 (0.61) | ALDH1A1HTTGAAKDM4ECYP19A1 | |
| SCHEMBL97980 | 0.64 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AKDM4ECYP19A1 | |
| SCHEMBL132509 | 0.64 | CYP19A1 (0.40) | ALDH1A1HTTLMNAKMT2AGAA | |
| SCHEMBL96811 | 0.63 | KMT2A (0.38) | ALDH1A1MCL1KMT2AMEN1CYP19A1 | |
| SCHEMBL98448 | 0.63 | CYP19A1 (0.36) | ALDH1A1MCL1KMT2ACYP19A1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | PPARG 1682/4885ALDH1A1 2458/4885MCL1 3284/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | PPARG 1682/4885ALDH1A1 2458/4885MCL1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.